

The Clinical Case for providing stop smoking support to Neurology Patients

Why intervene in secondary care?

1. Hospital patients are more receptive to 'Very Brief Advice' (VBA) and an offer of support to stop smoking, as they are often experiencing a period of heightened motivation
2. Giving VBA to a hospital patient (the '3 As': Ask, Advise, Act) can also encourage compliance to the smokefree hospital policy, and highlight any need for withdrawal management. Providing Nicotine Replacement Therapy (NRT) to a patient during a period of forced abstinence, will ease nicotine withdrawal symptoms
3. Stopping smoking can lead to significant health benefits, and reduce post-operative complications and improve recovery time

What is the aim of this 'clinical case' document?

The aim of this document is to provide clinical support for hospital staff in terms of supporting patients to stop smoking, even if this is just for a period of forced abstinence whilst in hospital. Being in hospital provides an opportune moment to intervene and provide both brief advice and support to stop smoking; including making a referral on to local stop smoking support. There are many benefits for a patient if they have temporary abstinence from smoking, including a shorter time for recovery and this can often stimulate a full attempt to stop smoking.

The Clinical Case for providing stop smoking support to Neurology Patients

What is the relationship between smoking and neurological disorders?

Cigarette smoke contains around 4,300 chemical compounds, at least 40 of which are carcinogenic, and also nicotine which is neuroactive. Nicotine binds to acetylcholinergic receptors, leading to increased activity of cholinergic neurones, acetylcholine receptor upregulation and dopamine release. Constituents of cigarette smoke can also affect the tissue and vasculature of the central nervous system by promoting atherosclerosis and thrombosis, and oxidative damage leading to increased lipid peroxidation. These processes, amongst others, have been implicated in diseases and disorders affecting the central nervous system.^{1,2}

Compared to those who don't smoke, smokers have been shown to be at an increased risk of the following:

- Ischemic or haemorrhagic stroke (around 50% increase in risk).³⁻⁵
- Subarachnoid haemorrhage (around a 100% increase in risk).^{6,7}
- Alzheimer's disease. Although early case-control studies indicated that smoking protected against Alzheimer's disease, more recent longitudinal studies have in fact showed that smoking increases the risk of Alzheimer's. An exception to this may be in people who carry the APO-E gene, where smoking doesn't appear to confer a greater risk above that of carrying the gene.^{8,9}
- Multiple sclerosis (around a 50% increased risk).¹⁰⁻¹²
- Amyotrophic lateral sclerosis (around a 50% increase in risk).^{13,14}
- Smokers are at greater risk of chronic pain, and experience pain in greater intensity when compared to never smokers.¹⁵

Despite the widely known detrimental effects of smoking on health, smokers have been found to be at about a 50% decreased risk of Parkinson's disease compared to those who don't smoke.^{16,17} The longer a person has smoked, the more their risk is reduced.¹⁸ The most likely mechanism for the protective effect of smoking is administration of nicotine.¹⁹

What are the health benefits of quitting for neurological patients?

Successfully stopping smoking will not only benefit a patient's long term health by reducing the risk of developing other diseases,²⁰ smoking abstinence may also help a patient recover quicker by eliminating the acute effects of smoking on the body and there is an evidenced benefit of stopping smoking in terms of neurological outcomes (see page 3).

The Clinical Case for providing stop smoking support to Neurology Patients**Main acute effects of smoking on the body
(estimated time of recovery, if known)**

- Increase in sympathetic tone leading to an increase in blood pressure, heart rate and peripheral vasoconstriction leading to an increased demand for oxygen and cardiac function.²¹
(24 – 48 hours)
- Formation of carboxyhaemoglobin leading to a reduction in oxygen delivery to the tissues.²²
(8 – 24 hours)
- Formation of carboxymyoglobin leading to a reduction in oxygen storage in the muscles.²³
(8 – 24 hours)
- Increase in red blood cell production, which leads to an increase in blood viscosity, a decrease in tissue perfusion, a decrease in oxygen delivery to the tissues and potentiation of thrombotic process.^{1,24}
- Hypersecretion of mucus, narrowing of the small airways, decrease in ciliary function and change in mucus rheology leading to a decrease in mucociliary transport.^{1,24} **(12 – 72 hours)**
- Changes in functioning of a range of immune cells (pro- and anti-inflammatory cytokines, white blood cells, immunoglobulins) which lead to decreased immunity and are associated with atherosclerosis.^{1,24} **(1 week – 2 months)**
- Induction of hepatic enzymes which increases drug metabolism through both pharmacokinetic and pharmacodynamic mechanisms.²⁵ **(6 – 8 weeks)**

Neurological health benefits associated with stopping smoking

- Stopping smoking is recommended for both primary and secondary prevention of stroke. The risk of stroke halves within the first year of stopping smoking, and after five years the risk is the same as for people who have never smoked.²⁶ The greatest benefit in stopping smoking is seen in heavy smokers who are also hypertensive.⁵
- Stopping smoking has been associated with improvement in symptoms and an improved prognosis in multiple sclerosis.^{27,28}
- Although smoking reduces the risk of developing Parkinson's disease, beneficial modification of the disease has not been demonstrated in patients who continue to smoke after diagnosis.^{19, 29}

The Clinical Case for providing stop smoking support to Neurology Patients

Providing 'Very Brief Advice' to hospital patients: the '3 A's'

Providing a stop smoking intervention to a hospital patient is proven to be effective regardless of the reason for admission.³⁰ Offering VBA is the single most cost effective and clinically proven preventative action a healthcare professional can take³¹ and it is important to keep giving advice at every opportunity, as smokers may take several attempts to stop smoking successfully.³² In addition, by referring a patient to a local stop smoking service, they are four times more likely to stop smoking.³³

Research shows that 95% of patients expect to be asked about smoking and a short intervention can make all the difference.^{34,35} The '3 A's' 30 second approach to giving 'very brief advice' are as follows:

ASK and record smoking status

ADVISE the patient of the personal health benefits of stopping smoking

ACT on the patient's response

- prescribe NRT for patients in withdrawal
- monitor withdrawal and adjust pharmacotherapy accordingly
- refer to local stop smoking service

How was this information sheet put together?

This information is a summary of the current scientific evidence on the association between cigarette smoking and neurological outcomes. Studies were found by searching MEDLINE and EMBASE using combined exploded subject headings of 'neurology', 'nervous system diseases', 'nervous system neoplasms' and 'tobacco use cessation' from 01/1990 – 09/2012 and by searching for key words in google scholar.

The Clinical Case for providing stop smoking support to Neurology Patients

References

1. Ambrose J. The pathophysiology of cigarette smoking and cardiovascular disease. *Journal of the American College of Cardiology* 2004; 43(10):1731–1737
2. Dome P et al Smoking, nicotine and neuropsychiatric disorders. *Neuroscience and Biobehavioral Reviews* 2010; 34: 295–342
3. Shinton R and Beever G Meta-analysis of relationship between cigarette smoking and stroke. *BMJ* 1989; 298:789–794
4. Kawachi I et al Smoking cessation and decreased risk of stroke in women. *JAMA* 1993; 269:232–236
5. Wolf PA et al Cigarette smoking as risk factor for stroke: the Framingham study. *JAMA* 1988; 259(7): 1025–1029
6. Feigin, VL et al Risk Factors for Subarachnoid Hemorrhage: An Updated Systematic Review of Epidemiological Studies. *Stroke* 2005, 36:2773–2780
7. Gijn, JV et al Subarachnoid haemorrhage. *Lancet* 2007; 369: 306–18
8. Cataldo JK et al Cigarette Smoking is a Risk Factor for Alzheimer's Disease: An Analysis Controlling for Tobacco Industry Affiliation. *J Alzheimers Dis* 2010; 19(2): 465–480
9. Merchant C et al The influence of smoking on the risk of Alzheimer's disease. *Neurology* 1999; 52: 7: 1408–1412
10. Hawkes CH Smoking is a risk factor for multiple sclerosis: a metanalysis. *Multiple Sclerosis* 2007; 13:610_615.
11. Riise T, Nortvedt MW, Ascherio A Smoking is a risk factor for multiple sclerosis. *Neurology* 2003 Oct 28;61(8):1122–4
12. Hernán, M et al Cigarette Smoking and Incidence of Multiple Sclerosis. *Am J Epidemiol* 2001;154:69–74
13. Wang H, O'Rielly EJ, Weisskopf MG et al Smoking and Risk of Amyotrophic Lateral Sclerosis: A Pooled Analysis of 5 Prospective Cohorts. *Archives of Neurology* 2011 VOL 68 (NO. 2), 207–213
14. Gallo v et al Smoking and risk of ALS: Analysis of the EPIC Cohort. *Ann Neurol* 2009; 65: 378–385.
15. Shi Y et al Smoking and pain: pathophysiology and clinical implications anesthesiology 2010; 113: 4: 977–992
16. Fratiglioni L, Wang HX Smoking and Parkinson's and Alzheimer's disease: a review of the epidemiological studies. *Behavioural Brain research* 2000; 113: 117–120
17. Hernan MA, Zhang SM et al Cigarette smoking and the incidence of Parkinson's disease in two prospective studie. *Annals of neurology* 2001; 50: 6:780–786
18. Chen H, Huang X, Guo X et al Smoking duration, intensity and risk of Parkinson disease. *Neurology* 2010; 74: 878–884
19. Quik M et al Multiple roles for nicotine in Parkinson's disease. *Biochemical Pharmacology* 2009; 78: 7: 677–685
20. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004; 328:1519
21. Warner DO. Perioperative abstinence from cigarettes: physiologic and clinical consequences. *Anesthesiology* 2006; 104:356–367
22. Rietbrock N, Kunkel S, Worner W, Eyer P. Oxygen-dissociation kinetics in the blood of smokers and non-smokers: interaction between oxygen and carbon monoxide at the hemoglobin molecule. *Nanunyn Scmiedebergs Arch Pharmacol* 1992; 98:528–534
23. Akrawi W, Benumof JL. A pathophysiological basis for informed preoperative smoking cessation counselling. *Journal of cardiothoracic and vascular anesthesia* 1997; 11(5):629–640
24. Moller A, Tonnesen H. Risk reduction: perioperative smoking intervention. *Best practice and research clinical anaesthesiology* 2006; 20(2):237–248
25. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. *Clinical Pharmacokinetics* 1999; 36(6):425–43

The Clinical Case for providing stop smoking support to Neurology Patients

26. Adams, Secondary prevention of atherothrombotic events after ischemic stroke. *May Clin Proc* 2009; 84(1): 43–51
27. Sundstrom P, Nystrom L Smoking worsens the prognosis in multiple sclerosis *Multiple Sclerosis* 2008; 14:1031–1035
28. Pittas et al Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. *J Neurol* (2009) 256:577–585
29. Alves G et al Cigarette smoking in parkinson's disease: influence on disease progression. *Movement Disorders* 2004; 19: 9: 1087–1092
30. Rigotti N, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database of Systematic Reviews* 2007; Issue3.Art.No.: CD001837.DOI:10.1002 /14651858.CD001837.pub2.
31. Anczakj, Nogler (2003). Tobacco cessation in primary care: maximizing intervention strategies. *Clinical Medicine & Research* 2003; 1: 201–216
32. Fu S, Partin M, Snyder A, An LC, Nelson DB, Clothier B, Nugent S, Willenbring ML, Joseph AM. (2006) Promoting repeat tobacco dependence treatment: are relapsed smokers interested? *American Journal of managed Care* 2006; 12 235–243
33. Smoking Toolkit Study (2001) Available at: <http://www.smokinginengland.info/>
34. Slama KJ, Redman S, Cockburn J, Sanson-Fisher R. Community views about the role of general practitioners in disease prevention. *Family Practice* 1989; 6: 203–209.
35. Department of Health (2009), Stop Smoking Interventions in Secondary Care. Available online: www.ncsct.co.uk/Content/FileManager/documents/NCSCT-CIC-Delivery-Projects/Secondary-care/stop-smoking-interventions-in-secondary-care-guidance-oct09.pdf